 | |
- close
- close
|
Business Wire
Nov 4
Comment
Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Global Research & Development Center, Inc., today announced data from a Phase 2 clinical trial of Hematide™ showing that Hematide increased hemoglobin and reduced or eliminated the need for
StreetInsider.com
Nov 4
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Affymax+%28AFFY%29+Posts+Q3+Loss+of+%240.97%2C+Narrower+than+Expected/5073153.html for the full story.
Business Wire
Nov 4
Comment
Affymax, Inc. (Nasdaq:AFFY) today reported financial results for the third quarter ended September 30, 2009. The net loss for the third quarter of 2009 was $18.4 million compared to a net loss of $26.2 million for the third quarter of 2008. Affymax
Business Wire
Nov 3
Comment
Affymax, Inc. (Nasdaq:AFFY) today announced the appointment of Hollings C. Renton to the position of chairman of the company’s board of directors effective December 1, 2009. Mr. Renton replaces Nick Galakatos, who served as lead board member since
Business Wire
Oct 30
Comment
Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Global Research & Development Center, Inc., today announced data from multiple clinical and preclinical studies evaluating Hematide, including preliminary results of a Phase 2 trial which
Business Wire
Oct 22
Comment
Affymax, Inc. (Nasdaq:AFFY) today announced multiple presentations at the American Society of Nephrology (ASN) Renal Week 2009 taking place October 27 through November 1 in San Diego. Affymax’s drug, Hematide™, is currently in development with
StreetInsider.com
Oct 6
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Upgrades/Argus+Upgrades+Affymax+%28AFFY%29+to+Buy+/4997459.html for the full story.
Business Wire
Sep 25
Comment
Affymax, Inc. (Nasdaq:AFFY) today announced that it has obtained an issuer managed equity facility under which it may sell up to $60 million of its registered common stock to Azimuth Opportunity, Ltd. Affymax is not obligated to utilize any of the
Business Wire
Sep 9
Comment
Affymax, Inc. (Nasdaq:AFFY) today announced that it has notified clinical trial sites to complete treatment of patients in the Phase 3 clinical program for the investigational drug, Hematide, by the end of 2009. The company expects a period of
StreetInsider.com
Aug 5
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Affymax+%28AFFY%29+Reports+Better-Than-Expected+Q2+Loss+of+%241.17/4846395.html for the full story.
|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
AFFY AT A GLANCE
References
| ||||||
|
|
